公开(公告)号：US11572541B2

公开(公告)日：2023-02-07

申请号：US16616932

申请日：2018-05-04

申请人： Providence Health & Services—Oregon ,  AgonOx, Inc.

发明人： Andrew D. Weinberg ,  Ryan Montier ,  Thomas Duhen ,  Rebekka Duhen

IPC分类号： C12N5/0783 ,  A61K35/17 ,  C07K14/725 ,  A61K48/00 ,  C12N15/10 ,  C12N15/85

摘要： Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8+CD39+CD103+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8+CD39+CD103+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8+CD39+CD103+ T cells. In addition, methods are disclosed for expanding CD8+CD39+CD103+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8+CD39+CD103+ T cells in a biological sample from a subject.